JP2019131544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019131544A5 JP2019131544A5 JP2019013745A JP2019013745A JP2019131544A5 JP 2019131544 A5 JP2019131544 A5 JP 2019131544A5 JP 2019013745 A JP2019013745 A JP 2019013745A JP 2019013745 A JP2019013745 A JP 2019013745A JP 2019131544 A5 JP2019131544 A5 JP 2019131544A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- formula
- acceptable salt
- diabetes
- compound represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 208000002249 Diabetes Complications Diseases 0.000 claims 8
- 206010012655 Diabetic complications Diseases 0.000 claims 8
- 206010019280 Heart failures Diseases 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 6
- 201000001421 hyperglycemia Diseases 0.000 claims 6
- 208000012268 mitochondrial disease Diseases 0.000 claims 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 206010002383 Angina Pectoris Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 4
- 206010007556 Cardiac failure acute Diseases 0.000 claims 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 4
- 206010007749 Cataract diabetic Diseases 0.000 claims 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000007025 diabetic cataract Diseases 0.000 claims 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 208000030175 lameness Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 2
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000021908 Myocardial disease Diseases 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000013824 Acidemia Diseases 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- -1 cyano, carboxy Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034806A JP2023071925A (ja) | 2018-02-01 | 2023-03-07 | 含窒素複素環アミド化合物及びその医薬用途 |
| JP2024094812A JP2024116307A (ja) | 2018-02-01 | 2024-06-12 | 含窒素複素環アミド化合物及びその医薬用途 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 | ||
| JP2018016328 | 2018-02-01 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034806A Division JP2023071925A (ja) | 2018-02-01 | 2023-03-07 | 含窒素複素環アミド化合物及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019131544A JP2019131544A (ja) | 2019-08-08 |
| JP2019131544A5 true JP2019131544A5 (enExample) | 2022-02-03 |
| JP7241556B2 JP7241556B2 (ja) | 2023-03-17 |
Family
ID=67479787
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019013745A Active JP7241556B2 (ja) | 2018-02-01 | 2019-01-30 | 含窒素複素環アミド化合物及びその医薬用途 |
| JP2023034806A Ceased JP2023071925A (ja) | 2018-02-01 | 2023-03-07 | 含窒素複素環アミド化合物及びその医薬用途 |
| JP2024094812A Pending JP2024116307A (ja) | 2018-02-01 | 2024-06-12 | 含窒素複素環アミド化合物及びその医薬用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034806A Ceased JP2023071925A (ja) | 2018-02-01 | 2023-03-07 | 含窒素複素環アミド化合物及びその医薬用途 |
| JP2024094812A Pending JP2024116307A (ja) | 2018-02-01 | 2024-06-12 | 含窒素複素環アミド化合物及びその医薬用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10800784B2 (enExample) |
| EP (1) | EP3747888A4 (enExample) |
| JP (3) | JP7241556B2 (enExample) |
| KR (1) | KR102725118B1 (enExample) |
| CN (1) | CN111655692B (enExample) |
| AR (1) | AR114237A1 (enExample) |
| AU (1) | AU2019214048B2 (enExample) |
| BR (1) | BR112020014177A2 (enExample) |
| CA (1) | CA3090219A1 (enExample) |
| CL (1) | CL2020002003A1 (enExample) |
| CO (1) | CO2020009420A2 (enExample) |
| IL (1) | IL276386B2 (enExample) |
| MX (1) | MX2020008126A (enExample) |
| MY (1) | MY205011A (enExample) |
| PE (1) | PE20211273A1 (enExample) |
| PH (1) | PH12020500613A1 (enExample) |
| SA (1) | SA520412473B1 (enExample) |
| SG (1) | SG11202006916SA (enExample) |
| TW (1) | TWI803570B (enExample) |
| WO (1) | WO2019151274A1 (enExample) |
| ZA (1) | ZA202004548B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3851103A4 (en) | 2018-09-11 | 2022-06-08 | Japan Tobacco Inc. | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| PL4097099T3 (pl) | 2020-02-07 | 2024-11-04 | Gasherbrum Bio, Inc. | Heterocykliczne agonisty glp-1 |
| EP4663189A2 (en) * | 2020-03-04 | 2025-12-17 | Japan Tobacco Inc. | Fused tricyclic compound and medicinal use thereof |
| JP2023540609A (ja) * | 2020-09-10 | 2023-09-25 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| CA3213837A1 (en) * | 2021-03-23 | 2022-09-29 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Heterocycle substituted ketone derivative, and composition and medicinal use thereof |
| TW202319051A (zh) | 2021-09-01 | 2023-05-16 | 日商日本煙草產業股份有限公司 | 含氮三環性化合物及其醫藥用途 |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) * | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| PE20090319A1 (es) * | 2007-06-01 | 2009-03-27 | Schering Corp | Moduladores de gamma secretasa |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| JP6147737B2 (ja) * | 2011-06-27 | 2017-06-14 | アレクトス・セラピューティクス・インコーポレイテッド | 選択的グリコシダーゼ阻害剤およびその使用 |
| WO2013074388A1 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| NZ630488A (en) * | 2012-06-12 | 2016-07-29 | Chong Kun Dang Pharm Corp | Piperidine derivatives for gpr119 agonist |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| EP3805205A1 (en) * | 2013-03-15 | 2021-04-14 | Japan Tobacco Inc. | Pyrazole-amide compound and medicinal uses therefor |
| TW201536748A (zh) * | 2013-07-01 | 2015-10-01 | Japan Tobacco Inc | 茀－醯胺化合物及其醫藥用途 |
| WO2015002119A1 (ja) | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | ピラゾール－アルコール化合物およびその医薬用途 |
| GB201316823D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| JP6527520B2 (ja) | 2013-12-17 | 2019-06-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピルビン酸脱水素酵素キナーゼの阻害剤としてのｎ１−（３，３，３−トリフルオロ−２−ヒドロキソ−２−メチルプロピオニル）−ピペリジン誘導体 |
| AU2016304182B2 (en) | 2015-07-31 | 2020-08-27 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| EP3436443B1 (en) | 2016-03-29 | 2020-03-11 | Merck Patent GmbH | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| AU2017258697B2 (en) * | 2016-04-28 | 2021-04-15 | Merck Patent Gmbh | Piperidinyl derivatives |
| CN114716377A (zh) * | 2016-07-29 | 2022-07-08 | 日本烟草产业株式会社 | 吡唑-酰胺化合物的制造方法 |
| WO2018034918A1 (en) * | 2016-08-15 | 2018-02-22 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| HUE050403T2 (hu) | 2016-10-28 | 2020-12-28 | H Lundbeck As | Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére |
| EP4663189A2 (en) * | 2020-03-04 | 2025-12-17 | Japan Tobacco Inc. | Fused tricyclic compound and medicinal use thereof |
| TW202319051A (zh) * | 2021-09-01 | 2023-05-16 | 日商日本煙草產業股份有限公司 | 含氮三環性化合物及其醫藥用途 |
-
2019
- 2019-01-30 AR ARP190100202A patent/AR114237A1/es unknown
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/es unknown
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/zh active Active
- 2019-01-30 KR KR1020207024426A patent/KR102725118B1/ko active Active
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/pt unknown
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/ja active Active
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/es unknown
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 TW TW108103504A patent/TWI803570B/zh active
- 2019-01-30 MY MYPI2020003575A patent/MY205011A/en unknown
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/ja not_active Ceased
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/ar unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/es unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/es unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/ja not_active Ceased
- 2023-09-05 US US18/460,821 patent/US20240300952A1/en not_active Abandoned
-
2024
- 2024-06-12 JP JP2024094812A patent/JP2024116307A/ja active Pending